drugset / Trial / NCT01027065
Dose Escalation of Interleukin-1 (IL-7) Added on Antiviral Treatment and Vaccination in HBeAg-negative Chronic Hepatitis B Virus (HBV) Infected Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is designed to evaluate the safety of biological active dose of a new experimental drug, IL-7, in combination with anti viral therapy and vaccine in patients with Hepatitis B chronic infection.
Timeline
- Start
- 2009-12
- Primary completion
- 2012-11
- Completion
- 2013-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GenHevac | Unknown | — | — |
| Subject | Interleukin-7 | Protein / enzyme biologic | — | Subcutaneous |
| Background | Entecavir | Small molecule | — | — |
| Background | Tenofovir | Small molecule | — | — |